Abstract:Background: Calcific aortic valve disease (CAVD) is an active pathobiological process that takes place at the cellular and molecular levels. It involves fibrosis and calcification of aortic valve leaflets, which eventually contributes to heart failure. Galectin-3 (Gal-3), a β-galactoside-binding lectin, is involved in myocardial fibrosis and remodeling. Our study aimed to explore how Gal-3 promoted the osteogenic differentiation of human aortic valve interstitial cells (hVICs) along with elucidating the underlying molecular mechanisms. Methods: To determine the Gal-3 expression in this study, we included the blood samples and aortic valves (AVs) from patients with CAVD (n=20) and normal controls (n=20). The hVICs were stimulated by Osteogenic medium (OM) and were treated with or without recombinant human Gal-3. Calcified transformation of hVICs was assessed by Alizarin Red S staining and osteogenic gene/protein expression. RNA-sequencing was performed for all different treatments to investigate differentially expressed genes (DEGs) along with exploring the enriched pathways for potential molecular targets of Gal-3. The targets were further detected using Western blotting and immunofluorescence staining. Results: Gal-3 levels were found to be significantly increased in CAVD patients. Treatment of valve interstitial cells (VICs) with Gal-3 led to a marked increase in Runx2 and ALP-mRNA/protein expression levels as well as calcification. Gene expression profiles of hVICs cultured with or without Gal-3 revealed 79 upregulated genes and 82 down-regulated genes, which were highly enriched in TNF and NF-κB signaling pathways. Furthermore, Gal-3 could activate the phosphorylation of IκBα and interfere with the translocation of p65 into the cell nucleus of hVICs. However, inhibition of this pathway can suppress the osteogenic differentiation by Gal-3. Conclusions: Gal-3 acts as a positive regulator of osteogenic differentiation by activating the NF-κB signaling pathway in hVICs. Our findings provide novel mechanistic insights into the critical role of Gal-3 in the CAVD progression.

Galectin-3 Contributes to the Inhibitory Effect of lα,25-(OH)2D3 on Osteoclastogenesis

Reduced form of Galectin-1 Suppresses Osteoclastic Differentiation of Human Peripheral Blood Mononuclear Cells and Murine RAW264 Cells In Vitro

1 Alpha,25-Dihydroxyvitamin D-3 Inhibits The Differentiation And Bone Resorption By Osteoclasts Generated From Wistar Rat Bone Marrow-Derived Macrophages

1α,25-Dihydroxyvitamin D3 inhibits the differentiation and bone resorption by osteoclasts generated from Wistar rat bone marrow-derived macrophages.

The role of galectin-3 in bone homeostasis: A review

Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity

Vitamin D Inhibition of TRPV5 Expression During Osteoclast Differentiation

Effects of Lanthanum on Formation and Bone-Resorbing Activity of Osteoclast-Like Cells

Galectin-3 Impairs Calcium Transients and Β-Cell Function

1α,25‐Dihydroxyvitamin D<sub>3</sub>Regulates the Expression of Membrane‐Type Matrix Metalloproteinase‐1 in Normal Human Osteoblast‐like Cells

1alpha,25-dihydroxyvitamin D3 regulates the expression of membrane-type matrix metalloproteinase-1 in normal human osteoblast-like cells.

Galectin-3 promotes calcification of human aortic valve interstitial cells via the NF-kappa B signaling pathway

Galectin-3 Enhances Osteogenic Differentiation of Precursor Cells from Patients with Diffuse Idiopathic Skeletal Hyperostosis Via Wnt/β-Catenin Signaling.

Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone

GALNT3 protects against phosphate-induced calcification in vascular smooth muscle cells by enhancing active FGF23 and inhibiting the wnt/β-catenin signaling pathway

1α,25‐Dihydroxyvitamin D3 Regulates the Expression of Membrane‐Type Matrix Metalloproteinase‐1 in Normal Human Osteoblast‐like Cells

Effects of Calcitriol on the Expression of Vitamin D Receptor. RANKL and Osteoprotegerin in Human Periodontal Ligament Cells

GALNT3 protects against vascular calcification by reducing oxidative stress and apoptosis of smooth muscle cells

[The Effects of 1Alpha,25-Dihydroxyvitamin D3 in Regulation Matrix Metalloproteinase and Tissue Metalloproteinase Inhibitors in Human Osteoblasts].

Osteoprotegerin Influences The Bone Resorption Activity Of Osteoclasts

Effects of 1a,25-Dihydroxyvitamin D3-26,23-Lactone and Its Intermediate Metabolites on Bone Metabolism in vivo and in vitro